Abstract:This article aims to define a value-based approach to pricing and reimbursement for off-patent originators using a multiple criteria decision analysis (MCDA) approach centered on a systematic analysis of current pricing and reimbursement policies in China. A drug price policy review was combined with a quantitative analysis of China's drug purchasing database. Policy preferences were identified through a MCDA performed by interviewing well-known academic experts and industry stakeholders. The study findings indicate that the current Chinese price policy includes cost-based pricing and the establishment of maximum retail prices and premiums for off-patent originators, whereas reference pricing may be adopted in the future. The literature review revealed significant differences in the dissolution profiles between originators and generics; therefore, dissolution profiles need to be improved. Market data analysis showed that the overall price ratio of generics and off-patent originators was around 0.54-0.59 in 2002-2011, with a 40 % price difference, on average. Ten differentiating value attributes were identified and MCDA was applied to test the impact of three pricing policy scenarios. With the condition of implementing quality consistency regulations and controls, a reduction in the price gap between high-quality off-patent products (including originator and generics) seemed to be the preferred policy. Patents of many drugs will expire within the next 10 years; thus, pricing will be an issue of importance for off-patent originators and generic alternatives.

Comparison of the Drug Price Administration Models Among Different Developed Countries

Comparative Study on the Policies of Drug Price and Expenditure Control in China and Other Countries

International Comparison of Drug Price Level in China

A comparative analysis of drug pricing and reimbursement in main European countries

Comparison of the Retail Drug Prices between China and Other Developed Countries or Districts

Comparison of Three Pricing Methods and Two Pricing Models foREssential Drugs

Experience and Enlightenment of Drug Price Regulation in Germany,Japan and Taiwan Area of China

Analysis of the "regulation of Drug Price Difference (trial Implementation)" in China

Research on the Problem of the Drug Price Management System in China and Its Optimization:Based on international comparison

International comparative study on high-value drugs payment system and its implications for China

Comparison of the policy of controlling fees of medicare drugs in China and the United States from the perspective of medical resource balance

Comparative analysis on the price of essential medicines:Based on the sample survey of primary health care institutions and pharmacies in 18 provinces

Study of Drug Price Regulation in China: an International Comparative Perspective

Method of new patent drug pricing and administration in China

Empirical Research of Price Difference and Market Share Between Brand-Name Drugs and Generics in One Province in China

A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators

Enlightenment of Drug Pricing and Drug Administration Policy in UK

Comparative Study on Essential Drug Centralized Bidding Purchase Plans of Provinces in China

The International Regulation Methods of Pharmaceutical Pricing and Their Impacts:A Systematic Review

Comparison of Drug Control Between China and USA

Study on Application of Pharmacoeconomic Evaluation in the Price Negotiation System of Patent Drugs